Pfizer's Monstrous Clinical Pipeline Is Harboring 2 Hidden Gems
Pfizer's mind-boggling size often results in promising clinical candidates getting swept under the rug, so to speak. Here is a look at two of the pharma giant's orphan drug candidates that haven't generated much talk among investors, despite being potential game-changers for their target indications.
3 Stocks That Could Double Your Money
Biotech has produced numerous stocks recently that have doubled or tripled in short periods of time. Here is a look at three small-cap companies with the potential to continue this trend.
Did BioMarin Bet on the Wrong Experimental DMD Drug?
Sarepta Therapeutics may hold a key advantage over BioMarin in the race to bring a game-changing Duchenne muscular dystrophy drug to market. Here's why.
Uh-Oh! Billionaire George Soros Just Stepped on Another Biotech Landmine
George Soros is one of the most closely watched figures in the investing world. Retail investors, though, shouldn't necessarily take cues from his hedge fund. Here's why.